Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Moodys
Baxter
Express Scripts
Dow
McKesson
Mallinckrodt

Last Updated: August 14, 2022

PATADAY TWICE DAILY RELIEF Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


When do Pataday Twice Daily Relief patents expire, and what generic alternatives are available?

Pataday Twice Daily Relief is a drug marketed by Alcon Labs Inc and is included in one NDA.

The generic ingredient in PATADAY TWICE DAILY RELIEF is olopatadine hydrochloride. There are seventeen drug master file entries for this compound. Thirty-eight suppliers are listed for this compound. Additional details are available on the olopatadine hydrochloride profile page.

Summary for PATADAY TWICE DAILY RELIEF
Drug patent expirations by year for PATADAY TWICE DAILY RELIEF
Recent Clinical Trials for PATADAY TWICE DAILY RELIEF

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Andover Research Eye InstitutePhase 4
AllerganPhase 4
McCabe Vision CenterN/A

See all PATADAY TWICE DAILY RELIEF clinical trials

Paragraph IV (Patent) Challenges for PATADAY TWICE DAILY RELIEF
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
PATADAY TWICE DAILY RELIEF Ophthalmic Solution olopatadine hydrochloride 0.1% 020688 1 2006-07-17

US Patents and Regulatory Information for PATADAY TWICE DAILY RELIEF

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Alcon Labs Inc PATADAY TWICE DAILY RELIEF olopatadine hydrochloride SOLUTION/DROPS;OPHTHALMIC 020688-001 Dec 18, 1996 OTC Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for PATADAY TWICE DAILY RELIEF

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Alcon Labs Inc PATADAY TWICE DAILY RELIEF olopatadine hydrochloride SOLUTION/DROPS;OPHTHALMIC 020688-001 Dec 18, 1996 See Plans and Pricing See Plans and Pricing
Alcon Labs Inc PATADAY TWICE DAILY RELIEF olopatadine hydrochloride SOLUTION/DROPS;OPHTHALMIC 020688-001 Dec 18, 1996 See Plans and Pricing See Plans and Pricing
Alcon Labs Inc PATADAY TWICE DAILY RELIEF olopatadine hydrochloride SOLUTION/DROPS;OPHTHALMIC 020688-001 Dec 18, 1996 See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for PATADAY TWICE DAILY RELIEF

See the table below for patents covering PATADAY TWICE DAILY RELIEF around the world.

Country Patent Number Title Estimated Expiration
Norway 970517 See Plans and Pricing
Hungary 201520 PROCESS FOR PRODUCING TRICYCLIC AROMATIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SUCH ACTIVE INGREDIENT See Plans and Pricing
European Patent Office 0235796 DIBENZ (B,E) OXEPIN DERIVATIVE AND ANTIALLERGIC AND ANTIINFLAMMATORY AGENT See Plans and Pricing
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for PATADAY TWICE DAILY RELIEF

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0799044 SPC029/2002 Ireland See Plans and Pricing SPC029/2002: 20040930, EXPIRES: 20170516
0799044 SPC/GB02/041 United Kingdom See Plans and Pricing SPC/GB02/041: 20021018
0799044 02C0040 France See Plans and Pricing PRODUCT NAME: OLOPATADINE HYDROCHLORIDE; REGISTRATION NO/DATE: EU/1/02/217/001 20020517
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Johnson and Johnson
Dow
Express Scripts
AstraZeneca
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.